Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis
| Autor: | Charissa Higdon, Karrie A. Hilsinger, David R. Sutton, Carla Nikkel |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Databases Factual Cost-Benefit Analysis medicine.medical_treatment 030209 endocrinology & metabolism Pharmacy Hypoglycemia V-Go 03 medical and health sciences chemistry.chemical_compound Basal-bolus Glycemic control 0302 clinical medicine Diabetes mellitus Internal medicine Outcome Assessment Health Care medicine Humans Hypoglycemic Agents Insulin Pharmacology (medical) 030212 general & internal medicine Retrospective Studies Original Research Glycemic Glycated Hemoglobin business.industry Diabetes Retrospective cohort study Infusion Pumps Implantable General Medicine Middle Aged Multiple daily injections medicine.disease United States Rheumatology Diabetes Mellitus Type 2 chemistry Female Insulin delivery Glycated hemoglobin business |
| Zdroj: | Advances in Therapy |
| ISSN: | 1865-8652 0741-238X |
| DOI: | 10.1007/s12325-018-0703-3 |
| Popis: | Introduction Advances in insulin delivery have improved outcomes in patients with diabetes. This study evaluated the impact of V-Go® Wearable Insulin Delivery device on glycated hemoglobin (A1C) and insulin total daily dose (TDD) in patients with diabetes not achieving glycemic targets. Methods Electronic medical record data was obtained for adult patients with A1C > 7% treated at a multicenter endocrine practice who initiated V-Go between August 2012 and August 2015. Data were collected at baseline and for up to four follow-up visits, and were analyzed overall, stratified by insulin use at baseline, and for patients prescribed a basal-bolus insulin regimen delivered by multiple daily injections (MDI) at baseline. Economic evaluations were conducted in patients previously prescribed MDI regimens. Results Patients (N = 103) were evaluated after a mean of 2, 6, 10, and 14 months of V-Go use. Baseline glycemic control was poor (A1C > 9%) in 59% of patients. Significant, sustained reductions in A1C compared with baseline were observed at every visit (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink